Tuesday Workshops
The ASCEPT Pharmacogenomics Special Interest Group Research Workshop
10:30 – 12:30
Chair: Prof Andrew Somogyi
| 10:30 – 10:35 | Welcome & introduction Prof Andrew Somogyi, Chair ASCEPT Pharmacogenomics SIG |
| 10:35 – 11:15 | Aboriginal genomic diversity and pharmacogenetics Prof Alan Cooper (Australian Centre for Ancient DNA, University of Adelaide) |
| 11:15- 11:35 | Old drugs, new tricks: a “golden” opportunity for chemotherapy pharmacogenomics? A/Prof Nuala Helsby (Molecular Medicine & Pathology, University of Auckland) |
| 11:35 – 11:50 | Pharmacogenetics of immunosuppressant uptake in graft tissue of renal transplant recipients A/Professor Benedetta Sallustio (Clinical Pharmacology, The Queen Elizabeth Hospital, Adelaide) |
| 11:50 – 12:05 | Pharmacogenetics in Papua New Guinea HIV/AIDS patients: an update Helena van Schalkwyk (Discipline of Pharmacology, University of Adelaide) |
| 12:05 – 12:30 | Pharmacogenomics SIG AGM |
Careers and Early Stage Biomedical Translation
Part of the Accelerating Australia National Conference
10:30 – 16:45
| 10:30 – 12:15 | Biomedical Entrepreneurship How an entrepreneurial mindset can help you strategise for your future career |
| 12:15 – 12:45 | Lunch |
| 12:45 – 14:30 | Accelerating Australia Early Stage Innovation Showcase Pitches from Accelerating Australia course participants |
| 14:30 – 15:00 | Afternoon tea |
| 15:00 – 16:45 | Working with Industry Showcasing success stories from the current ecosystem |
Prescribing Safety Assessment Workshop
incorporating Clinical Pharmacology Workshop
10:30 – 16:45
| 10:30 – 11:15 | Overview of the PSA and progress to date Assoc Prof Claire Harrison, Monash University/ Prof Sarah Hilmer, The University of Sydney |
| 11:15 – 11:30 | ASCEPT and the PSA Prof Carl Kirkpatrick, ASCEPT |
| 11:30 – 12:30 | Timelines and infrastructure for 2019 and beyond Assoc Prof Matt Doogue, University of Otago |
| 12:30 – 13:30 | Lunch (own expense) |
| 13:30 – 14:15 | PSA item creation Assoc Prof Claire Harrison |
| 14:15 – 15:15 | Standard-setting Assoc Prof Claire Harrison |
| 15:15 – 15:30 | AOB Further thoughts on the future Prof Sarah Hilmer, Assoc Prof Claire Harrison, Assoc Prof Matt Doogue |
| 16:00 – 16:45 | Clinical Pharmacology SIG AGM |
Education Forum
Hit the ground running… How do we embed WIL in our pharmacology programs?
13:00 – 16:45
The workshop will start with a talk from Professor Janice Orrell about the value of WIL and include discussion of how pharmacology relevant WIL opportunities can be incorporated into our science/biomedical science degree programs, particularly those with large enrolments. The session will also include feedback about what is happening in our various institutions.
Chair: Liz Davis
Guest speaker: Prof Janice Orrell, Professor of Higher Education, Flinders University
University educators are under growing pressure to ensure that our students are “work-ready” and to provide opportunities for authentic learning. Within the health profession courses, this can, to some extent be achieved by clinical placements. However, with the more general degrees such as science and biomedical science, internships and placements can be harder to establish and maintain. We need to identify other ways of providing an authentic learning experience for our students. Central to this is ensuring academics can see beyond discipline-specific knowledge are on board with both the concept and the practice of WIL. This workshop will explore the value of Work Integrated Learning (WIL) and how we can embed this within our large science/biomedical science courses.
Education Forum AGM 16:00
Keynote speakers
Prof Daria Mochly-Rosen
Stanford University, USA
Daria Mochly-Rosen is a Professor of Chemical and Systems Biology and the George D. Smith Professor for Translational Medicine at Stanford University School of Medicine. She leads a multi-disciplinary research lab that includes chemists, biochemists, biologists and physician scientists and has used her basic research discoveries to develop a number of drug leads for human diseases with a particular interest in mitochondrial biology and pathology. Dr Mochly-Rosen served on many university leadership committees, was chair of her department (2001-2004) and the Senior Associate Dean for Research, Stanford University School of Medicine (between 2006 and 2013). She has published over 240 papers and over 30 patents and patent applications and has founded three companies: KAI Pharmaceuticals (2003-2011), ALDEA (now Aviv Therapeutics; 2013-) and Mitoconix (2016-).
Prof Steven Charlton,
School of Life Sciences, University of Nottingham, UK
Steven is Professor of Molecular Pharmacology and Drug Discovery at the University of Nottingham, where he is interested in all aspects of the quantitative assessment of ligand-receptor interactions. In particular he has expertise in the measurement and interpretation of the kinetics of ligand binding and signalling. Steven is also co-founder and Chief Scientific Officer at Excellerate Bioscience Ltd, a CRO providing specialist molecular pharmacology solutions to the drug discovery sector. Prior to these roles he spent 16 years in the pharmaceutical industry, both at SmithKline Beecham and Novartis. At Novartis he was Director of Molecular Pharmacology in Respiratory Diseases, leading an assay development and compound profiling team of 30 scientists providing expert opinion and support for GPCR, ion channel and enzyme projects. He has broad drug discovery experience, ranging from target validation through to leading full lead optimisation programmes to successful clinical proof of concept. Steven was awarded Novartis Leading Scientist in 2007.
Dr John Thompson
National Poisons Information Service, UK
Dr John Thompson is Director of the National Poisons Information Service (Cardiff), one of four units responsible for delivering advice on the management of poisoned patients within the United Kingdom and which also provides services internationally. He is the national lead for the United Kingdom Poisons Information Database (UKPID) and was previously Head of the Chemical Incident Management Support Unit, advising on the management of chemical incidents and is a consultant to the World Health Organisation Collaborating Centre for the Public Health Management of Chemical Exposures. Dr Thompson is Senior Lecturer in Clinical Pharmacology at Cardiff University. Clinically, in addition to providing general internal medicine services, Dr Thompson is the lead consultant for a specialised eight-bedded poisons treatment unit and delivers specialty clinics in toxicology, hypertension and adverse drug reactions.
Prof Andrew McLachlan
The University of Sydney School of Pharmacy, AUS
Professor Andrew McLachlan is a pharmacist, academic and researcher with experience in clinical pharmacology and the quality use of medicines. He is Head of School and Dean at The University of Sydney School of Pharmacy. Andrew is the Program Director of a NHMRC Centre for Research Excellence in Medicines and Ageing. He has served as the chair of a human research ethics committee and serves on Australian government committees related to medicines policy, evaluation, regulation and antidoping. He became a Member of the Order of Australia for his significant service to pharmacy as a researcher, educator and administrator, and to professional medical and scientific organisations.